Literature DB >> 22142401

Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine.

Q Tian1, N D Price, L Hood.   

Abstract

A grand challenge impeding optimal treatment outcomes for patients with cancer arises from the complex nature of the disease: the cellular heterogeneity, the myriad of dysfunctional molecular and genetic networks as results of genetic (somatic) and environmental perturbations. Systems biology, with its holistic approach to understanding fundamental principles in biology, and the empowering technologies in genomics, proteomics, single-cell analysis, microfluidics and computational strategies, enables a comprehensive approach to medicine, which strives to unveil the pathogenic mechanisms of diseases, identify disease biomarkers and begin thinking about new strategies for drug target discovery. The integration of multidimensional high-throughput 'omics' measurements from tumour tissues and corresponding blood specimens, together with new systems strategies for diagnostics, enables the identification of cancer biomarkers that will enable presymptomatic diagnosis, stratification of disease, assessment of disease progression, evaluation of patient response to therapy and the identification of reoccurrences. Whilst some aspects of systems medicine are being adopted in clinical oncology practice through companion molecular diagnostics for personalized therapy, the mounting influx of global quantitative data from both wellness and diseases is shaping up a transformational paradigm in medicine we termed 'predictive', 'preventive', 'personalized', and 'participatory' (P4) medicine, which requires new strategies, both scientific and organizational, to enable bringing this revolution in medicine to patients and to the healthcare system. P4 medicine will have a profound impact on society - transforming the healthcare system, turning around the ever escalating costs of healthcare, digitizing the practice of medicine and creating enormous economic opportunities for those organizations and nations that embrace this revolution.
© 2011 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22142401      PMCID: PMC3978383          DOI: 10.1111/j.1365-2796.2011.02498.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  46 in total

Review 1.  Properties of developmental gene regulatory networks.

Authors:  Eric H Davidson; Michael S Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-22       Impact factor: 11.205

2.  Chimeric transcript discovery by paired-end transcriptome sequencing.

Authors:  Christopher A Maher; Nallasivam Palanisamy; John C Brenner; Xuhong Cao; Shanker Kalyana-Sundaram; Shujun Luo; Irina Khrebtukova; Terrence R Barrette; Catherine Grasso; Jindan Yu; Robert J Lonigro; Gary Schroth; Chandan Kumar-Sinha; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-10       Impact factor: 11.205

3.  Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics.

Authors:  Paola Picotti; Bernd Bodenmiller; Lukas N Mueller; Bruno Domon; Ruedi Aebersold
Journal:  Cell       Date:  2009-08-06       Impact factor: 41.582

4.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

5.  Recurring mutations found by sequencing an acute myeloid leukemia genome.

Authors:  Elaine R Mardis; Li Ding; David J Dooling; David E Larson; Michael D McLellan; Ken Chen; Daniel C Koboldt; Robert S Fulton; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Devin P Locke; Vincent J Magrini; Rachel M Abbott; Tammi L Vickery; Jerry S Reed; Jody S Robinson; Todd Wylie; Scott M Smith; Lynn Carmichael; James M Eldred; Christopher C Harris; Jason Walker; Joshua B Peck; Feiyu Du; Adam F Dukes; Gabriel E Sanderson; Anthony M Brummett; Eric Clark; Joshua F McMichael; Rick J Meyer; Jonathan K Schindler; Craig S Pohl; John W Wallis; Xiaoqi Shi; Ling Lin; Heather Schmidt; Yuzhu Tang; Carrie Haipek; Madeline E Wiechert; Jolynda V Ivy; Joelle Kalicki; Glendoria Elliott; Rhonda E Ries; Jacqueline E Payton; Peter Westervelt; Michael H Tomasson; Mark A Watson; Jack Baty; Sharon Heath; William D Shannon; Rakesh Nagarajan; Daniel C Link; Matthew J Walter; Timothy A Graubert; John F DiPersio; Richard K Wilson; Timothy J Ley
Journal:  N Engl J Med       Date:  2009-08-05       Impact factor: 91.245

6.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

7.  Circulating microRNAs, potential biomarkers for drug-induced liver injury.

Authors:  Kai Wang; Shile Zhang; Bruz Marzolf; Pamela Troisch; Amy Brightman; Zhiyuan Hu; Leroy E Hood; David J Galas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-25       Impact factor: 11.205

8.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

9.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

10.  A systems approach to prion disease.

Authors:  Daehee Hwang; Inyoul Y Lee; Hyuntae Yoo; Nils Gehlenborg; Ji-Hoon Cho; Brianne Petritis; David Baxter; Rose Pitstick; Rebecca Young; Doug Spicer; Nathan D Price; John G Hohmann; Stephen J Dearmond; George A Carlson; Leroy E Hood
Journal:  Mol Syst Biol       Date:  2009-03-24       Impact factor: 11.429

View more
  58 in total

1.  End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.

Authors:  Vural Ozdemir; Erik Fisher; Edward S Dove; Hilary Burton; Galen E B Wright; Mario Masellis; Louise Warnich
Journal:  Curr Pharmacogenomics Person Med       Date:  2012-01-01

2.  Advances in biotechnology and linking outputs to variation in complex traits: Plant and Animal Genome meeting January 2012.

Authors:  R Appels; R Barrero; M Bellgard
Journal:  Funct Integr Genomics       Date:  2012-02-22       Impact factor: 3.410

Review 3.  Personalized oncology in interventional radiology.

Authors:  Nadine Abi-Jaoudeh; Austin G Duffy; Tim F Greten; Elise C Kohn; Timothy W I Clark; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2013-08       Impact factor: 3.464

Review 4.  A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.

Authors:  James T Yurkovich; Qiang Tian; Nathan D Price; Leroy Hood
Journal:  Nat Rev Clin Oncol       Date:  2019-10-16       Impact factor: 66.675

Review 5.  Principles and methods of integrative genomic analyses in cancer.

Authors:  Vessela N Kristensen; Ole Christian Lingjærde; Hege G Russnes; Hans Kristian M Vollan; Arnoldo Frigessi; Anne-Lise Børresen-Dale
Journal:  Nat Rev Cancer       Date:  2014-05       Impact factor: 60.716

6.  Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.

Authors:  Jia-Xuan Qiu; Zhi-Wei Zhou; Zhi-Xu He; Ruan Jin Zhao; Xueji Zhang; Lun Yang; Shu-Feng Zhou; Zong-Fu Mao
Journal:  Drug Des Devel Ther       Date:  2015-01-07       Impact factor: 4.162

Review 7.  Managing large-scale genomic datasets and translation into clinical practice.

Authors:  T Lecroq; L F Soualmia
Journal:  Yearb Med Inform       Date:  2014-08-15

8.  The ABRF Metabolomics Research Group 2013 Study: Investigation of Spiked Compound Differences in a Human Plasma Matrix.

Authors:  Amrita K Cheema; John M Asara; Yiwen Wang; Thomas A Neubert; Vladimir Tolstikov; Chris W Turck
Journal:  J Biomol Tech       Date:  2015-09

9.  Mass Spectrometry-based Proteomics and Peptidomics for Systems Biology and Biomarker Discovery.

Authors:  Robert Cunningham; Di Ma; Lingjun Li
Journal:  Front Biol (Beijing)       Date:  2012-08-01

Review 10.  Is phosphoproteomics ready for clinical research?

Authors:  Anton B Iliuk; W Andy Tao
Journal:  Clin Chim Acta       Date:  2012-11-13       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.